Bibliographic information
GuidelineWHO guidelines for malaria, 25 November 2022.
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
Originally developed
Short-course standard high-dose primaquine treatment: To prevent relapse, WHO recommends against an additional treatment option of using primaquine 1.0 mg/kg/ day for seven days to treat P. vivax or P. ovale malaria.
Recommended against
Conditional
Certainty of evidence
Very low
Notes and Remarks
Remark
- There is a significantly increased risk of serious adverse events (moderate to large undesirable effect) at this daily dosing of the standard high dose.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO Guidelines for malaria, 14 March 2023
Year2023
InstitutionWHO